Application of rhenium-188 HEDP in bone metastases therapy

Nuclear Medicine Review

Volumn 6, Issue 1, 2003, Pages 55-57

  Scheffler, Justyna ^a   Derejko, Mirosława ^a   Bandurski, Tomasz ^a   Romanowicz, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bone metastases radionuclide therapy

Indexed keywords

ANALGESIC AGENT; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; OPIATE; RHENIUM 188; STRONTIUM 89; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DOSIMETRY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FEVER; HUMAN; KNEE PAIN; LEUKOPENIA; NAUSEA; NONHUMAN; NUCLEAR MEDICINE; NUCLEAR REACTOR; PHARMACIST; REVIEW; THROMBOCYTOPENIA; VOMITING;

BONE NEOPLASMS; ETIDRONIC ACID; HUMANS; LEUKOPENIA; ORGANOMETALLIC COMPOUNDS; PAIN; PALLIATIVE CARE; PHYSICIAN'S PRACTICE PATTERNS; RADIOPHARMACEUTICALS; RHENIUM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037670023     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Namer M. Clinical consequences of osteolytic bone metastases. Bone 1991; 12: 57.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-66.
3. Pecher C. Biological investigations with radioactive calcium and strontium. Proc Soc Exp Biol Med 1941; 46: 86-91.
4. Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. U Cal Pub Pharmacol 1942; 11: 117-149.
5. Pauwels EKJ. Stokkel MPM. Radiopharmaceuticals for bone lesions. Q J Nucl Med 2001; 45: 18-26.
6. Lin WY, Lin CP, Yeh SJ, Hsieh BT, Tsai ZT, Ting G et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med. 1997; 24: 590-595.
7. Knapp FF, Beets AL., Guhlke S, Zamora PC, Bender H, Palmedo H et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labelled radiopharmaceuticals for cancer treatment. Anticancer Res 1997; 17: 1783-1795.
8. Maxon HR, Schroder LE, Washburn LC, Thomas SR, Samaratunga RC, Biniakiewicz D et al. Rhenium-188 (Sn)HEDP for treatment of osseous metastases. J Nucl Med 1998; 39: 659-663.
9. Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF Jr. Simple new method for effective concentration of 188Re solutions from alumina-based 188W-188Re generator. J Nucl Med 2000; 41: 1271-1278.
10. Hsieh BT, Hsieh JF, Tsai S.C., Lin WY, Wang SJ, Ting G. Comparison of various rhenium-188-labelled diphosphonates for the treatment of bone metastases. Nucl Med Biol 1999; 26: 973-976.
11. Prakash S, Went MJ, Blower PJ. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Nucl Med Biol 1996; 23: 543-549.
12. Iznaga-Escobar N. Direct radiolabelling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors - a review of radiolabelling characteristics, quality control and in vitro stability studies. Appl Radiat Isot 2001; 54: 399-406.
13. Lin WY, Hsieh JF, Lin CP, Hsieh BT, Ting G, Wang SJ, Knapp FF Jr. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes. Nucl Med Biol. 1999; 26: 455-459.
14. Savio E, Gaudiano J, Robles AM, Balter H, Paolino A, López A et al. Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nuclear Medicine 2001; 1: 2.
15. Roka R, Sera T, Pajor L, Thurzo L, Lang J, Csernay L et al. Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain. Orv Hetil 2000; 141: 1019-1923.
16. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin 2000; 39: 146-151.
17. Li S, Liu J, Zhang H, Tian M, Wang J. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 2001; 26: 919-922.
18. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27: 123-130.
19. Palmedo H, Albers P, Ghulke S, Reinhardt MJ, Klemm E, Matthies A et al. Treatment of bone metastases in prostate cancer patient with rhenium-188 HEDP. 15th Annual Congress of the European Association of Nuclear Medicine, Austria, Vienna, August 31 September 4, 2002.